Analysts forecast that R1 RCM Inc (NASDAQ:RCM) will announce sales of $305.10 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for R1 RCM’s earnings, with estimates ranging from $304.70 million to $305.60 million. R1 RCM reported sales of $295.00 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 3.4%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, August 4th.
According to Zacks, analysts expect that R1 RCM will report full-year sales of $1.20 billion for the current fiscal year, with estimates ranging from $1.16 billion to $1.25 billion. For the next financial year, analysts forecast that the company will report sales of $1.43 billion, with estimates ranging from $1.33 billion to $1.54 billion. Zacks’ sales averages are a mean average based on a survey of research firms that follow R1 RCM.
R1 RCM (NASDAQ:RCM) last announced its earnings results on Tuesday, May 5th. The healthcare provider reported $0.05 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.08 by ($0.03). R1 RCM had a return on equity of 174.42% and a net margin of 2.44%. The business had revenue of $320.50 million for the quarter, compared to analyst estimates of $318.76 million. During the same period in the previous year, the company earned ($0.04) earnings per share. The company’s quarterly revenue was up 16.1% compared to the same quarter last year.
NASDAQ RCM traded down $0.17 during mid-day trading on Friday, hitting $10.59. The stock had a trading volume of 1,804,625 shares, compared to its average volume of 1,068,032. The firm’s 50 day moving average is $10.78 and its 200 day moving average is $11.35. R1 RCM has a twelve month low of $7.12 and a twelve month high of $13.99. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 14.63.
Institutional investors and hedge funds have recently modified their holdings of the business. Citigroup Inc. grew its holdings in shares of R1 RCM by 38.6% during the 1st quarter. Citigroup Inc. now owns 194,233 shares of the healthcare provider’s stock worth $1,765,000 after purchasing an additional 54,090 shares during the period. Balyasny Asset Management LLC purchased a new position in shares of R1 RCM during the 1st quarter worth $320,000. State Street Corp grew its holdings in shares of R1 RCM by 0.6% during the 1st quarter. State Street Corp now owns 2,270,718 shares of the healthcare provider’s stock worth $20,641,000 after purchasing an additional 13,685 shares during the period. Two Sigma Advisers LP grew its holdings in shares of R1 RCM by 59.1% during the 1st quarter. Two Sigma Advisers LP now owns 785,200 shares of the healthcare provider’s stock worth $7,137,000 after purchasing an additional 291,600 shares during the period. Finally, UBS Group AG grew its holdings in shares of R1 RCM by 61.3% during the 4th quarter. UBS Group AG now owns 132,189 shares of the healthcare provider’s stock worth $1,715,000 after purchasing an additional 50,260 shares during the period. 74.28% of the stock is owned by institutional investors and hedge funds.
About R1 RCM
R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers.
Featured Story: What is an investor looking for in an SEC filing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.